ClinicalTrials.gg
CompletedNCT04803708REVERSEUpdated Oct 4, 2022

Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers

A Phase 1/2 interventional study of TP-102 in Diabetic Foot Ulcer, Pseudomonas Aeruginosa Infection and Staphylococcus Aureus Infection, sponsored by Technophage, SA. Completed at 2 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-04.

Sponsored by Technophage, SA · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Diabetic Foot with a site in Israel — none open to participants now, 2 under way, none of them phase 3. Diabetic Foot · Israel.

Enrollment
13th of 18
20 · median 25
Started
2021
with 2 others
Phase 1/2
4 of 21
none open now
Registered
16th of 21
by date

Among the 21 studies in Diabetic Foot with a site in Israel, this one is the 13th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2021, is one of 4 in phase 1/2, and was the 16th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

None of the 21 studies in Diabetic Foot with a site in Israel is open now. The open studies under Diabetic Foot, anywhere →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Diabetic Foot with a site in Israel as a file.
02

Study summary

This is a Phase I/IIa trial designed to evaluate topical bacteriophage therapy in patients with diabetic foot ulcers.

Read the detailed description

The primary objective of this study is to evaluate the safety of a topical bacteriophage cocktail in the treatment of non infected and infected diabetic foot ulcers with Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumanni. Patients will also be evaluated for bacterial clearance and wound reduction.

03

Conditions studied

  • Diabetic Foot Ulcer
  • Pseudomonas Aeruginosa Infection
  • Staphylococcus Aureus Infection
  • Acinetobacter Infection

Keywords

  • Bacteriophage therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Both cohorts:

  • Type 1 or type 2 diabetes mellitus with (HbA1c) ≤10, 5%
  • Suitable physical and mental health as determined by the investigator based on medical history and general physical examination.
  • Subjects must be medically stable based on clinical laboratory tests, medical history and vital signs. Clinical laboratory tests should be within normal values or not , unless directly related to the condition of diabetes.
  • Female subjects must fulfil one of the following criteria:

    1. At least 1 year (amenorrhea >12 months prior to screening);
    2. Surgically sterile (bilateral oophorectomy or hysterectomy);
    3. If of , must agree to use a highly effective method of from screening until 14 days after the last administration of IP.
  • Female subjects of childbearing potential must have a negative pregnancy test at screening.
  • Male subjects with a female partner of child-bearing potential or pregnant partner must agree to use a condom from screening until 14 days after the last IP application.
  • ICF signed voluntarily before any study-related procedure is performed, indicating that the subject understands the purpose of, and procedures required for the study and is willing to participate in the study.

Part A:

  • Non-infected diabetic foot ulcer perfusion grade 1, depth grade 1 and infection grade 1 according to PEDIS classification.

Part B

  • Infected diabetic foot ulcer meeting perfusion grade 1 or 2, depth grade 1 or 2 and infection 2 or 3,except if presence of abscess, fasciitis, osteomyelitis, and septic arthritis, according to PEDIS definition.
  • Infected with at least one bacterial strain susceptible to bacteriophage cocktail assessed from culture.

Exclusion criteria

Exclusion Criteria:

Both cohorts:

  • Study ulcer less than 2 cm away from other ulcers in case of multiple ulcers.
  • History in the 5 previous years of any cancer requiring systemic chemotherapy or radiation.
  • A condition that, in the opinion of the Investigator, could compromise the well being of the subject or course of the study, or prevent the subject from meeting or performing any study requirements.
  • subjects due to illness, organ transplant, or immune suppressive therapies (e.g. oral or parental , methotrexate, immune modulators) 3 months prior to screening. Ad hoc low dose inhaled corticosteroids or topical corticosteroids are not allowed from 2 weeks prior to randomization.
  • Being pregnant or breastfeeding.
  • Currently participating in another clinical trial or having participated in a previous clinical trial with receipt of an product within 30 days of the first administration of IP or 5 half-lives, whichever is longer.
  • Subjects that, in the opinion of the Investigator or their treating physician, are dependent of the following therapies for their ulcer treatment:

    • Topical antimicrobial treatment (including isobetadine gel/dressing, silver nitrate dressing, topical antibiotic)
    • Enzymatic, autolytic, maggot debridement
    • Any active wound healing products (e.g., Dermagraft, Apligraf, Regranex, or Tegaderm hydrogel or others.)
    • Physical or cleansing modalities, antiseptics, corticosteroids, growth factors, solutions other than sterile normal saline and ulcer treatments.

Part A:

  • Clinically infected ulcers

Part B:

  • Suspected or confirmed abscess, fasciitis, osteomyelitis or septic arthritis.
  • Subjects meeting grade 3 or above PEDIS perfusion criteria
  • Planed or anticipated surgery after screening
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Part A- Cohort 1

    8 eligible subjects with non-infected DFU will be enrolled (Cohort 1) and receive IP three times weekly (TIW) every other day for up to one week. Of these 8 enrolled subjects, 6 subjects will be randomized to TP-102 and 2 to placebo. Subjects will be followed-up for 7 days.

    Biological: TP-102

  • Experimental
    Part B- Cohort 2

    18 subjects with a DFU with a grade 2 or 3 infection, as per PEDIS classification, and at least one bacterial strain susceptible to bacteriophage cocktail will be included in Cohort 2. Subjects will receive IP TIW, every other day, up to four weeks and will be randomized at a 2:1 randomization rate to either: * TP-102 q.d 3x weekly up to four weeks (n=12) * Placebo q.d. 3x weekly up to four weeks (n=6) Subjects will be followed-up for 7 days.

    Biological: TP-102

Interventions

  • BiologicalTP-102

    One mL of IP solution will be applied topically per cm3 of target ulcer. The titer of each bacteriophage in TP 102 is 1x10\^9 plaque forming units per milliliter (PFU/mL).

06

What researchers measure

Primary outcomes

  1. 1. Incidence and severity of treatment-emergent solicited local and systemic AEs and relationship to IP from first administration until 1 week after end of treatment (EOT) (end of study -EOS)

    Local AEs include erythema/redness, swelling/induration, pain and tenderness Systemic AEs include fatigue, myalgia, fever, headache and gastrointestinal symptoms (nausea, vomiting, diarrhea)

    Time frame: 1 week

  2. 2. Incidence and severity of treatment-emergent unsolicited AEs and relationship to IP from first administration until EOS.

    Time frame: 1 week

  3. 3. Incidence and severity of treatment-emergent SAEs and relationship to IP from first administration until EOS.

    Time frame: 1 week

Secondary outcomes

  1. Proportion of subjects with significant reduction or eradication from baseline in microbiologic data via culture (cfu) at d3, d8, d15, d22, d26 and EOS

    Time frame: 35 days

  2. Time (days) to significant reduction or eradication of target bacteria via culture.

    Time frame: 35 days

  3. Changes in wound/ulcer healing from to baseline in terms of wound size and depth (cm^3) at EOT.

    Time frame: 35 days

  4. Changes in wound/ulcer healing from to baseline in terms of wound complete closure and partial closure (25%, 50% and 75%) at EOT.

    Time frame: 35 days

07

Study locations

2 sites
  • Hadassah Medical Center, Ein Kerem
    Jerusalem, 91091, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Aug 2022, 16 months.

Of 18 phase 1/2 interventional studies under Diabetic Foot, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 37. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2021
First posted
Mar 18, 2021
StartActual
Mar 22, 2021
Primary completionActual
Aug 7, 2022
CompletionActual
Sep 5, 2022
Last update
Oct 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04803708
Lead sponsor
Technophage, SA
Collaborators
VectorB2B
Responsible party
Sponsor
First posted
Mar 18, 2021
Start date
Mar 22, 2021
Primary completion
Aug 7, 2022
Completion
Sep 5, 2022
Last update
Oct 4, 2022

Study contacts

Ran Nir-Paz, MD
principal investigator · Hadassah Medical Organization
Ronen Ben Ami, MD
principal investigator · Tel-Aviv Sourasky Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion